1. Intensive Care Unit Outcomes and Mortality in Elderly Oncological Patients.
- Author
-
Arif Timuroğlu, Selda Muslu, Ayşegül Danacı, Erce Can Üresin, and Süheyla Ünver
- Subjects
- *
ARTIFICIAL respiration , *OLDER patients , *CANCER patients , *INTENSIVE care units , *AGE groups , *INTENSIVE care patients - Abstract
Introduction: The number of elderly patients taken to intensive care unit (ICU) is gradually increasing due to the prolongation of life expectancy. According to UK data, the majority of newly diagnosed cancer patients are people over the age of 65, and the highest incidence of cancer is in people between the ages of 85 and 89. The aim of our study is to reveal the ICU outcomes, mortality in oncological patients over 65 years of age, and to document the predisposing factors that cause mortality. Materials and Methods: After the ethics committee approval was obtained, the data of oncology patients over the age of 65 who were treated in ICU between 01/01/2020 and 12/31/2021 were retrospectively analyzed. Results: Of the total 706 patients treated in ICU, 174 were oncology patients over the age of 65. There were 98 people in the 65-74 age range and 76 people over the age of 75. Although patients over 75 years of age had higher APACHE II scores, hospital and ICU mortality rates were similar to those of the other age group. Among the factors affecting ICU and hospital mortality, it was significant that patients used vasoactive drugs at any time and needed invasive mechanical ventilation support. Hospital mortality was found to be lower in cancer patients who underwent surgery in the last 6 months than in patients who did not undergo surgery. Conclusion: Mortality is quite high in ICU treatment of elderly critically ill patients with cancer. In this retrospective study, it was seen that the mortality rate of oncological patients over 65 years of age who were treated in ICU was over 70%. It was found that the mortality risk was more than 2 times higher in patients requiring invasive mechanical ventilation and vasoactive drugs. There was no difference in mortality between solid and hematological cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2023